Skip to content
Abierto
Menu

Justification

Anthrax Antitoxin (monoclonal antibody)

75A50324C00006

Office of Assistant Secretary for Preparedness and Response, Aspr/Orm-Sns. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Elusys Therapeutics Inc.

$124,523,123.01 obligated so far on USAspending, April 30, 2024, contract 75A50324C00006

Description

As published on SAM.gov.

Justification and Approval relating to procurement of FDA-approved anthrax antitoxin (monoclonal antibody) is hereby published in accordance with FAR 6.305(a).

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Elusys Therapeutics Inc.
UEI
ELP1DCK8L191
CAGE
1WEK8
Vendor location
Parsippany, NJ
Contract
75A50324C00006, definitive contract
Obligated
$124,523,123.01
Actions
8 between April 30, 2024 and July 7, 2026
Competition
Not Competed, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Anthim (Obiltoxaximab)
Match
award number 75A50324C00006 equals the contract number; same awarding office 75A503 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. May 3, 2024

    Justification

    SAM.gov, notice f9028949d84b4a9ebb1d2319a7bd2afa

Points of contact

Also open from this buyer